Navigating Medicare Part D changes: Opportunities for pharma
The Inflation Reduction Act (IRA) is bringing changes to Medicare Part D, including a cap on annual patient out-of-pocket (OOP) costs and the Medicare Prescription Payment Plan (MPPP). These changes present opportunities and challenges for pharmaceutical companies. The new Part D benefit design could improve patient affordability, level the playing field with medical benefit competitors, and reduce reliance on patient assistance programs. However, the MPPP's complexity may create confusion for patients.
Pharmaceutical companies should quantify the impact, identify benefiting patients, educate stakeholders, and reevaluate assistance programs to improve drug affordability and access. Read the blog to learn more.